Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.56 |
| ▸ | CTSK | P43235 | 3/20 | 0.56 |
| ▸ | CTSB | P07858 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5551983 | 0.86 | CTSS (0.54) | CTSSCTSKCTSBCTSLKMT2A | |
| SCHEMBL464398 | 0.82 | CTSS (0.63) | CTSSCTSKCTSBCTSLKMT2A | |
| SCHEMBL14775736 | 0.82 | CTSS (0.63) | CTSSCTSKCTSBCTSLKMT2A | |
| SCHEMBL9383811 | 0.81 | CTSS (0.58) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL9383807 | 0.81 | CTSS (0.58) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL5557583 | 0.81 | CTSK (0.50) | CTSSCTSKCTSBCTSLKMT2A | |
| SCHEMBL20962930 | 0.80 | CTSS (0.49) | CTSSCTSKCTSBCTSLKMT2A | |
| SCHEMBL5555644 | 0.79 | CTSK (0.48) | CTSSCTSKCTSBCTSLKMT2A | |
| SCHEMBL4214524 | 0.79 | CTSS (0.70) | CTSSCTSKCTSBCTSLATM | |
| SCHEMBL4214520 | 0.79 | CTSS (0.70) | CTSSCTSKCTSBCTSLATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070014721-A1 | Hydrazide conjugates as imaging agents | CA14, CA13, CA1 | CTSS 1532/4885CTSK 1070/4885CTSB 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.